摘要
为观察依立替康 (lrinotecan ,CPT Ⅱ )联合顺铂 (DDP)二线治疗小细胞肺癌 (small celllungcancer ,SCLC)的疗效和不良反应 ,对 2 2例既往经一线化疗方案治疗失败的SCLC患者采用CPT Ⅱ 60mg/m2 ,静脉滴入 ,d1、d8、d15;DDP 60mg/m2 ,静脉滴入 ,d1化疗。 2 8d为 1个周期 ,至少完成 2个周期以上。 2 2例患者中除 1例出现Ⅳ度腹泻退出化疗 ,2 1例患者均完成所需周期化疗。其中 1例CR ,8例PR ,有效率 (CR +PR) 42 9% (9/2 1)。常见治疗毒性为乙酰胆碱综合征 (9 1% ,2 /2 2 )、延迟性腹泻 (18.2 % ,4/2 2 )、Ⅱ～Ⅲ度白细胞减少 (81 8% ,18/2 2 )和Ⅱ～Ⅲ度中性粒细胞减少 (72 .7% ,16/2 2 )、仅 1例出现Ⅳ度腹泻 ,主要为血液学毒性。初步研究结果提示 ,CPT Ⅱ联合DDP作为二线化疗方案治疗SCLC有效 ,毒副反应可以耐受。
The objective is to observe the efficacy and adverse effects of irinotecan plus cisplatin for small cell lung cancer as second line treatment.Twenty two patients who previously failed with first line treatment were received irinotecan 60 mg/m 2 on d 1,d 8,d 15 ,and cisplatin 60 mg/m 2 on d 1,28 days which was one cycle,and each patient should finished two cycles at least.Twenty two patients finished the treatment except one. One patient showed CR and eight patients showed PR among the 21 patients,giving an effective rate of 42 9%(9/21).The common adverse effects were cholinergic syndrome (9 1%,2/22)and delayed diarrhea (18 2%,4/22), and only one patient developed grade Ⅳ diarrhea.The main toxicity was hematological toxicity i.e. grade Ⅱ-Ⅲ leukapenra(81 8%,18/22),Ⅱ-Ⅲ neutropen (72 7%,16/22).In conclusion,the combinations of irinotecan and cisplatin are feasible,will tolerated for small cell cancer as second line treatment.
出处
《肿瘤防治杂志》
CAS
2004年第1期89-90,共2页
China Journal of Cancer Prevention and Treatment
关键词
肺肿瘤
药物疗法
癌
小细胞
药物疗法
喜树碱
类似物和衍生物
顺铂
投药和剂量
lung neoplasms/drug therapy
carcinoma, small cancer/drug therapy
camptothecin/analogs & derivatives
cisplatin/administration & dosage
